ZA200607422B - Treatment regimen for camptothecin derivatives - Google Patents
Treatment regimen for camptothecin derivatives Download PDFInfo
- Publication number
- ZA200607422B ZA200607422B ZA200607422A ZA200607422A ZA200607422B ZA 200607422 B ZA200607422 B ZA 200607422B ZA 200607422 A ZA200607422 A ZA 200607422A ZA 200607422 A ZA200607422 A ZA 200607422A ZA 200607422 B ZA200607422 B ZA 200607422B
- Authority
- ZA
- South Africa
- Prior art keywords
- dose
- camptothecin derivative
- patient
- once
- days
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title claims description 28
- 238000011269 treatment regimen Methods 0.000 title description 3
- 229950009073 gimatecan Drugs 0.000 claims description 35
- UIVFUQKYVFCEKJ-OPTOVBNMSA-N gimatecan Chemical group C1=CC=C2C(\C=N\OC(C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UIVFUQKYVFCEKJ-OPTOVBNMSA-N 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 230000002062 proliferating effect Effects 0.000 claims description 11
- 230000009885 systemic effect Effects 0.000 claims description 8
- 238000012423 maintenance Methods 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 description 12
- 101710183280 Topoisomerase Proteins 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229940127093 camptothecin Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000006510 metastatic growth Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000010013 cytotoxic mechanism Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- -1 imino methyl camptothecin Chemical compound 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55672904P | 2004-03-26 | 2004-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200607422B true ZA200607422B (en) | 2007-12-27 |
Family
ID=34963082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200607422A ZA200607422B (en) | 2004-03-26 | 2006-09-05 | Treatment regimen for camptothecin derivatives |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080262014A1 (ko) |
| EP (1) | EP1732554A2 (ko) |
| JP (1) | JP2007530495A (ko) |
| KR (1) | KR20070010133A (ko) |
| CN (2) | CN1929842A (ko) |
| AU (2) | AU2005226932B2 (ko) |
| BR (1) | BRPI0509240A (ko) |
| CA (1) | CA2559532A1 (ko) |
| IL (1) | IL178106A0 (ko) |
| MA (1) | MA28533B1 (ko) |
| NO (1) | NO20064907L (ko) |
| RU (1) | RU2006137657A (ko) |
| TN (1) | TNSN06305A1 (ko) |
| WO (1) | WO2005092302A2 (ko) |
| ZA (1) | ZA200607422B (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050418A1 (it) * | 2005-08-04 | 2007-02-05 | Sigma Tau Ind Farmaceuti | Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69901379T2 (de) * | 1999-03-09 | 2002-11-07 | Sigma Tau Ind Farmaceuti | Camptothecin-Derivate mit Antitumor-Wirkung |
-
2005
- 2005-03-24 AU AU2005226932A patent/AU2005226932B2/en not_active Ceased
- 2005-03-24 WO PCT/EP2005/003183 patent/WO2005092302A2/en active Application Filing
- 2005-03-24 EP EP05716376A patent/EP1732554A2/en not_active Withdrawn
- 2005-03-24 CA CA002559532A patent/CA2559532A1/en not_active Abandoned
- 2005-03-24 BR BRPI0509240-0A patent/BRPI0509240A/pt not_active IP Right Cessation
- 2005-03-24 RU RU2006137657/15A patent/RU2006137657A/ru not_active Application Discontinuation
- 2005-03-24 CN CNA2005800081703A patent/CN1929842A/zh active Pending
- 2005-03-24 CN CNA2008101850224A patent/CN101480395A/zh active Pending
- 2005-03-24 KR KR1020067019794A patent/KR20070010133A/ko not_active Application Discontinuation
- 2005-03-24 US US10/592,832 patent/US20080262014A1/en not_active Abandoned
- 2005-03-24 JP JP2007504370A patent/JP2007530495A/ja active Pending
-
2006
- 2006-09-05 ZA ZA200607422A patent/ZA200607422B/en unknown
- 2006-09-14 IL IL178106A patent/IL178106A0/en unknown
- 2006-09-25 TN TNP2006000305A patent/TNSN06305A1/en unknown
- 2006-10-13 MA MA29387A patent/MA28533B1/fr unknown
- 2006-10-26 NO NO20064907A patent/NO20064907L/no not_active Application Discontinuation
-
2009
- 2009-06-30 AU AU2009202656A patent/AU2009202656A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2006137657A (ru) | 2008-05-10 |
| CN1929842A (zh) | 2007-03-14 |
| US20080262014A1 (en) | 2008-10-23 |
| CN101480395A (zh) | 2009-07-15 |
| WO2005092302A3 (en) | 2006-08-03 |
| JP2007530495A (ja) | 2007-11-01 |
| MA28533B1 (fr) | 2007-04-03 |
| TNSN06305A1 (en) | 2007-12-03 |
| AU2009202656A1 (en) | 2009-07-23 |
| WO2005092302A2 (en) | 2005-10-06 |
| AU2005226932A1 (en) | 2005-10-06 |
| KR20070010133A (ko) | 2007-01-22 |
| CA2559532A1 (en) | 2005-10-06 |
| AU2005226932B2 (en) | 2009-07-09 |
| EP1732554A2 (en) | 2006-12-20 |
| NO20064907L (no) | 2006-12-20 |
| BRPI0509240A (pt) | 2007-09-04 |
| IL178106A0 (en) | 2006-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120157472A1 (en) | Method for treating colorectal cancer | |
| US20230079055A1 (en) | Combination of bi853520 with chemotherapeutic drugs | |
| KR20140079831A (ko) | 췌장암 및／또는 담도암 치료약 | |
| KR20130043225A (ko) | 복합 항암 요법 | |
| US20210353627A1 (en) | Novel quinazoline egfr inhibitors | |
| CA2985379C (en) | Micronized pharmaceutical compositions for treatment of angiogenisis conditions | |
| AU2005226932B2 (en) | Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen | |
| JP7420888B2 (ja) | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 | |
| KR102669822B1 (ko) | 세포 증식성 질환의 치료 또는 예방을 위한 쿠마린 유도체 | |
| US20230038138A1 (en) | Combination therapy for treating cancer | |
| US20040033271A1 (en) | Methods for contemporaneous administration of levamisole and 5-fluorouracil | |
| US7338955B1 (en) | Medicament for treatment of neuropathies | |
| MXPA06010902A (en) | Treatment regimen for camptothecin derivatives | |
| MX2013004924A (es) | Combinacion de bevacizumab y 2,2-dimetil-n((s)-6-oxo-6,7-dihidro-5 h-dibenzo[b,d] azepin-7-il)-n'-(2,2,3,3,3-pentafluoro-propil)-malo namida para el tratamiento de desordenes proliferativos. | |
| EP1485090B1 (en) | Combinations comprising an epothilone derivative and an imidazotetrazinone | |
| US20040266704A1 (en) | Method comprising irinotecan for treatment of breast cancer | |
| AU2002225902B2 (en) | Methods for contemporaneous administration of levamisole and 5-fluorouracil | |
| US20030065000A1 (en) | Method of treating cancer | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| WO2021053523A1 (en) | Compositions and methods to improve the therapeutic benefit of bis-dioxopiperazines | |
| RU2020124923A (ru) | Применение нового ингибитора тирозинкиназ, анлотиниба, при остеосаркоме и хондросаркоме | |
| AU2002225902A1 (en) | Methods for contemporaneous administration of levamisole and 5-fluorouracil |